SwissMedic-2021-0049-V349

Type IB variation for application SwissMedic-2021-0049. Type IB variation: Formulation Change for Brextanib — major revision

Variation Number
SwissMedic-2021-0049-V349
Type
Type IB
Application
SwissMedic-2021-0049
Change
CHG-2024-0049
Status
Completed
Fee
€3,070
Submitted
2022-08-06
Approved
—
Description

Type IB variation: Formulation Change for Brextanib — major revision